Transgene Presented Additional Phase I Data
with TG4050 (myvac® platform) at ASCO 2022
Enterome presents proof-of-concept immune response data and first clinical data from Phase 1/2 trial with EO2401, a first-in-class OncoMimics™ therapeutic cancer vaccine for adrenocortical carcinoma, at ASCO 2022
Transgene Presented Additional Phase I Data with TG4050 (myvac® platform) at ASCO 2022
Immutep reports positive Overall Response Rate
in its Phase II clinical trial in 1st line NSCLC for PD-L1 all-comers
